Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

PLXP


Top 10 Correlated ETFs

PLXP


Top 10 Correlated Stocks

PLXP


In the News

01:56 30 Sep 2022 PLXP

PLx Pharma Inc. (PLXP) CEO, Natasha Giordano on Q2 2022 Results - Earnings Call Transcript

PLx Pharma Inc. (NASDAQ:PLXP ) Q2 2022 Earnings Conference Call August 12, 2022 8:30 AM ET Company Participants Janet Barth - Vice President, Investor Relations & Corporate Communications Natasha Giordano - President & Chief Executive Officer Rita O'Connor - Chief Financial Officer & Head, Manufacturing & Supply Chain Asif Ali - Preventative Cardiologist Conference Call Participants Jason Butler - JMP Securities Leland Gershell - Oppenheimer Elliot Wilbur - Raymond James Operator Hello, ladies and gentlemen. Thank you for standing by and welcome to the PLx Pharma Second Quarter 2022 Earnings Conference Call.

09:47 30 Sep 2022 PLXP

PLx Pharma, Inc. (PLXP) Reports Q2 Loss, Lags Revenue Estimates

PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 7.14% and 86.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

01:25 30 Sep 2022 PLXP

PLx Pharma (PLXP) CEO, Natasha Giordano on Q1 2022 Results - Earnings Call Transcript

PLx Pharma Inc. (NASDAQ:PLXP ) Q1 2022 Earnings Conference Call May 13, 2022 8:30 AM ET Company Participants Natasha Giordano - President, Chief Executive Officer Rita O'Connor - Chief Financial Officer Mike Valentino - Executive Chairman Asif Ali - Preventative Cardiologist Janet Barth - Vice President, Investor Relations Conference Call Participants Leland Gershell - Oppenheimer Elliot Wilbur - Raymond James Jason Butler - JMP Securities Operator Ladies and gentlemen, thank you for standing by and welcome to PLx Pharma's first quarter 2022 earnings conference call. At this time, all participants are in a listen-only mode.

09:47 30 Sep 2022 PLXP

PLx Pharma, Inc. (PLXP) Reports Q1 Loss, Lags Revenue Estimates

PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 4.35% and 11.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

06:50 30 Sep 2022 PLXP

PLx Pharma Inc. to Discuss 2022 First Quarter Financial Results on May 13, 2022 Conference Call and Provide Business Update

SPARTA, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that it will release its 2022 first quarter financial results before the opening of the U.S. financial markets on Friday, May 13, 2022. Company executives will host a conference call at 8:30am ET that day with institutional investors and analysts to provide an overview of PLx Pharma's performance for the quarter, along with a business update.

12:27 30 Sep 2022 PLXP

PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q4 2021 Results - Earnings Call Transcript

PLx Pharma Inc. (PLXP) CEO Natasha Giordano on Q4 2021 Results - Earnings Call Transcript

09:47 30 Sep 2022 PLXP

Dipexium Pharmaceuticals, Inc. (PLXP) Reports Q4 Loss, Misses Revenue Estimates

Dipexium Pharmaceuticals, Inc. (PLXP) delivered earnings and revenue surprises of -5.80% and 17.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

06:50 30 Sep 2022 PLXP

PLx Pharma Inc. to Present at Oppenheimer & Co's 32nd Annual Healthcare Conference on March 15, 2022

SPARTA, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that Natasha Giordano, President and CEO of PLx Pharma Inc. and Rita O'Connor, Chief Financial Officer & Head of Manufacturing & Supply Chain, will present on March 15, 2022, at Oppenheimer & Co's 32nd Annual Healthcare Conference, which will be a virtual event this year.

04:30 30 Sep 2022 PLXP

PLx Pharma Inc. to Discuss 2021 Fourth Quarter Financial Results on March 11, 2022 Conference Call and Provide Business Update

SPARTA, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that it will release its 2021 fourth quarter financial results before the opening of the U.S. financial markets on Friday, March 11, 2022. Company executives will host a conference call at 8:30am ET that day with institutional investors and analysts to provide an overview of PLx Pharma's performance for the quarter, along with a business update.

10:49 30 Sep 2022 PLXP

Implied Volatility Surging for Dipexium Pharmaceuticals (PLXP) Stock Options

Investors need to pay close attention to Dipexium Pharmaceuticals (PLXP) stock based on the movements in the options market lately.

Financial details

Company Rating
Neutral
Market Cap
14.68M
Income
-40.72M
Revenue
10.77M
Book val./share
1.17
Cash/share
1.29
Dividend
-
Dividend %
-
Employees
16
Optionable
No
Shortable
Yes
Earnings
10 Nov 2022
P/E
-0.36
Forward P/E
-
PEG
0.28
P/S
1.35
P/B
0.45
P/C
0.41
P/FCF
-0.25
Quick Ratio
3.99
Current Ratio
4.57
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.52
EPS next Y
-
EPS next Q
-
EPS this Y
-1.5%
EPS next Y
-
EPS next 5Y
777.63%
EPS last 5Y
-4.78%
Revenue last 5Y
60.17%
Revenue Q/Q
-76.81%
EPS Q/Q
10.26%
-
-
-
-
SMA20
-40.66%
SMA50
-77.5%
SMA100
-82.41%
Inst Own
47.43%
Inst Trans
-5.27%
ROA
-91%
ROE
-94%
ROC
-1.79%
Gross Margin
37%
Oper. Margin
-589%
Profit Margin
-378%
Payout
-
Shs Outstand
28.17M
Shs Float
20.69M
-
-
-
-
Target Price
-
52W Range
0.51-21.189
52W High
-
52W Low
-
RSI
30.3
Rel Volume
0.36
Avg Volume
352.1K
Volume
127.36K
Perf Week
-12.61%
Perf Month
-49.48%
Perf Quarter
-85.36%
Perf Half Y
-87.06%
-
-
-
-
Beta
3.99401
-
-
Volatility
0.03%, 0.16%
Prev Close
-0.87%
Price
0.5254
Change
9.44%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0.110.090.0600.3
Net income per share
-2.190.1-2.3-1.57-1.71
Operating cash flow per share
-1.9-1.09-1.42-1.26-1.19
Free cash flow per share
-1.97-1.16-1.45-1.27-1.19
Cash per share
3.481.631.572.312.58
Book value per share
0.660.740.181.081.92
Tangible book value per share
0.360.5-1.59-1.341.84
Share holders equity per share
0.660.740.181.081.92
Interest debt per share
1.150.950.590.10
Market cap
45.63M46.98M51.57M52.27M153.67M
Enterprise value
28.17M39.92M41.85M30.44M84.27M
P/E ratio
-2.9752.41-2.52-3.44-3.33
Price to sales ratio
58.662.3991.21.72K18.72
POCF ratio
-3.43-4.95-4.07-4.27-4.78
PFCF ratio
-3.3-4.63-4-4.23-4.78
P/B Ratio
9.897.2932.8652.97
PTB ratio
9.897.2932.8652.97
EV to sales
36.1853.0174.011K10.27
Enterprise value over EBITDA
-1.8717.8-2.16-2.1-1.84
EV to operating cash flow
-2.12-4.2-3.31-2.49-2.62
EV to free cash flow
-2.03-3.93-3.24-2.47-2.62
Earnings yield
-0.340.02-0.4-0.29-0.3
Free cash flow yield
-0.3-0.22-0.25-0.24-0.21
Debt to equity
1.50.660.400
Debt to assets
0.840.651.651.410.33
Net debt to EBITDA
1.16-3.150.51.511.51
Current ratio
14.153.142.346.496.19
Interest coverage
-13.6-9.57-14.27-43.710
Income quality
0.87-10.60.620.80.7
Dividend Yield
0000.030
Payout ratio
000-0.110
Sales general and administrative to revenue
13.0710.3517.73300.710
Research and developement to revenue
5.345.218.38142.590.51
Intangibles to total assets
0.070.110.110.080.03
Capex to operating cash flow
0.040.070.020.010
Capex to revenue
-0.69-0.87-0.43-3.350
Capex to depreciation
0-3.26-1.53-0.250
Stock based compensation to revenue
2.091.121.5542.340.35
Graham number
5.691.313.026.168.61
ROIC
-0.59-0.8-1.14-0.58-0.63
Return on tangible assets
-0.570.05-1.25-0.62-0.62
Graham Net
0.040.27-1.86-1.551.71
Working capital
23.87M10.13M8.19M19.44M61.6M
Tangible asset value
2.56M4.38M-14.15M-12.99M49.62M
Net current asset value
1.46M2.92M-16.31M-14.56M48.51M
Invested capital
1.51.122.730.060
Average receivables
00000
Average payables
785.39K757.81K895.74K862.57K5.73M
Average inventory
194.88K00143.38K1.3M
Days sales outstanding
9.098.8412.06028.19
Days payables outstanding
0000805.2
Days of inventory on hand
0000186.72
Receivables turnover
40.1741.330.27012.95
Payables turnover
00000.45
Inventory turnover
00001.95
ROE
-3.320.14-13.06-1.46-0.89
Capex per share
-0.08-0.07-0.03-0.010

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
00.250.060.080.02
Net income per share
-0.7-0.80.13-0.39-0.43
Operating cash flow per share
-0.23-0.33-0.49-0.61-0.65
Free cash flow per share
-0.23-0.33-0.49-0.61-0.65
Cash per share
3.393.072.521.911.29
Book value per share
2.371.741.881.521.17
Tangible book value per share
2.291.671.81.451.1
Share holders equity per share
2.371.741.881.521.17
Interest debt per share
00000
Market cap
326.21M519.4M220.53M111.26M67.3M
Enterprise value
246.04M436.84M151.14M58.76M31.57M
P/E ratio
-4.94-615.48-2.58-1.42
Price to sales ratio
078.51138.5353.41139.33
POCF ratio
-59.56-57.73-16.5-6.59-3.72
PFCF ratio
-59.56-57.73-16.5-6.59-3.72
P/B Ratio
5.8111.074.272.652.07
PTB ratio
5.8111.074.272.652.07
EV to sales
066.0394.9428.2165.35
Enterprise value over EBITDA
69.35-20.2541.78-5.48-2.68
EV to operating cash flow
-44.92-48.55-11.31-3.48-1.74
EV to free cash flow
-44.92-48.55-11.31-3.48-1.74
Earnings yield
-0.05-0.040.02-0.1-0.18
Free cash flow yield
-0.02-0.02-0.06-0.15-0.27
Debt to equity
00000
Debt to assets
0.340.490.330.310.27
Net debt to EBITDA
-22.63.83-19.184.893.03
Current ratio
26.7611.976.194.364.57
Interest coverage
000-6.07K-501.31
Income quality
0.330.42-3.751.571.53
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00.230.430.311.15
Intangibles to total assets
0.020.020.030.030.05
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00.110.640.522.17
Graham number
6.115.622.343.673.36
ROIC
-0.08-0.12-0.32-0.38-0.41
Return on tangible assets
-0.2-0.240.05-0.18-0.28
Graham Net
2.181.531.681.310.94
Working capital
78.95M81.21M61.6M44.52M32.41M
Tangible asset value
54.07M44.85M49.62M39.92M30.44M
Net current asset value
52.83M43.69M48.51M38.87M29.44M
Invested capital
00000
Average receivables
01.98M666K698K594K
Average payables
7.55M9.58M11.66M12.72M10.46M
Average inventory
2.55M3.01M3.15M3.84M3.86M
Days sales outstanding
044.2635.8430.1691.3
Days payables outstanding
0148.411.07K978.99901.32
Days of inventory on hand
050.38247.93295.56426.18
Receivables turnover
02.032.512.980.99
Payables turnover
00.610.080.090.1
Inventory turnover
01.790.360.30.21
ROE
-0.29-0.460.07-0.26-0.36
Capex per share
00000

Frequently Asked Questions

What is PLx Pharma Inc. stock symbol ?

PLx Pharma Inc. is a US stock , located in Sparta of New jersey and trading under the symbol PLXP

What is PLx Pharma Inc. stock quote today ?

PLx Pharma Inc. stock price is $0.5254 today.

Is PLx Pharma Inc. stock public?

Yes, PLx Pharma Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap